Showing posts with label journal of breast cancer. Show all posts
Showing posts with label journal of breast cancer. Show all posts

Tuesday, 11 July 2017

Breast Cancer and Pregnancy: Experience of Maternity and Neonatology Center of Tunis-Tunisia

This document aims to identify the clinical, therapeutic, and prognostic features of this association and to provide the up-to-date management.

Breast Cancer

Our study design is retrospective based on 25 cases of pregnancy-associated breast cancer, carried out at the Maternity and Neonatology Center of Tunis over a period of 10 years, between January 2001 and December 2013.

The mean age of the patients was 35.84 years. Breast cancer was diagnosed during pregnancy in fourteen patients and after delivery in eleven patients. Pathohistological diagnosis was established by ultrasoundguided biopsy and surgical biopsy in fourteen and seven patients, respectively.


Wednesday, 24 May 2017

Metaplastic Breast Cancer and p16 Positivity: What Does It Mean?

Metaplastic breast cancer is a heterogeneous group of malignant breast tumors having different morphologic subtypes. Considerable variations exist in different ethnic groups.
Metaplastic Breast Cancer

The incidence of metaplastic breast cancer is reported to be 0.2-1 percent of breast cancer and it is rare in the west.

MBC is referred to tumor when conventional breast carcinoma contains a metaplastic component ranging from <10% - >50%

Friday, 24 March 2017

Medico-legal Aspects of Delay in Diagnosis of Breast Cancer

lymphoedema impact factor

As a capricious and heterogeneous disease breast cancer may be difficult to diagnose and despite being appropriately treated may relapse unexpectedly.

Governmental pressure to reduce waiting for women with breast cancer may lead some patients to suspect that very short delays may impact adversely on their prognosis.

In this supercharged atmosphere of anxiety, communicational skills of breast surgeons may be constantly tested so that minor solecisms may translate into major patient dissatisfaction.

Thursday, 3 November 2016

Breast-Conserving Therapy Versus Radical Mastectomy for Early Breast Cancer

The aim of this clinical study was to compare breast-conserving therapy (BCT) and radical mastectomy (RM) in the treatment of early breast cancer. Materials and methods: From March 1986 to the end of 1989, 117 women with a breast tumor of up to 2 cm in size were included in this study; 66 women had a quadrantectomy, while 51 had a radical mastectomy.

Early Breast Cancer
Full axillary dissection was performed in all patients, while adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil was conducted in node-positive patients. Radiation to the remaining breast parenchyma consisted of external-beam therapy, with or without regional irradiation, without boost to the tumor bed. Results: The follow-up of patients in the two treatment groups was limited to 240 months.

The mean period of observation (SD±) was 201.34 months (54.12 ± 226.5) for the patients with breast-conserving therapy (BCT) and 195.84 months (35.1 ± 226.5) for the patients with radical mastectomy.

Thursday, 27 October 2016

The Challenge of pN3 Stage in Breast Cancer

Since 1959 the American Joint Committee on Cancer (AJCC) TNM system has been used to stage breast cancer. Since then, the TNM has helped clinicians in deciding the better treatment for each patient.

pN3 Stage in Breast Cancer
Periodically revisions have been made to this classification with the aim of keeping a relationship between the disease extent and the prognosis. However, when we talk about breast cancer, the TNM is not always enough.Several publications in the last years report that there are other predictive factors that influence the prognosis, measured by the overall survival or the DFS (disease-free survival), as much as the TNM stage does.

Some authors claim that important factors as primary tumor histologic grade and biologic tumor markers should be included in the AJCC system.

Friday, 16 September 2016

The Prognostic Role of Tumor-Infiltrating Lymphocytes CD8 and Foxp3 and their Impact on Recurrence in Breast Cancer Patients

The presence of tumor-infiltrating lymphocytes (TILs) either within the tumor stroma or tumor epithelium reflects the immune response of the host against the tumor, defined as cancer “immunoediting”. Large tumors are in the “escape” phase during which immune cells are not able to stop tumor growth but their presence at least denotes standby immunocompetency which can be reactivated by treatment.

Breast Cancer Patients
Many TILs have been recognized. Of those, fork head box P3- positive (Foxp3+) regulatory T cells (Tregs), CD8+ T cells, and CD4+ T cells are known to be the main keys for immune surveillance and tolerance, respectively [4]. CD8+ T cells are mediators of antitumor immunity and can lyse tumor cells directly. The clinical importance of CD8+ T cells has been suggested by many recent studies that reported a survival benefit in correlation with an increase in CD8+ T cells in large cohorts of various human cancer patients.

CD4+ T cells have an important role in antitumor immunity that was implicated by their helper or memory cell functions. CD4+ T cells may have several effector functions, such as priming tumor-specific cytotoxic T cells or macrophages that are involved in clearance of tumor cells. In contrast, Tregs are known to have a very important role in escape of antitumor T-cell response in cancer cells [13], due to their ability to potently suppress immune reaction against tumors in vivo.

Wednesday, 10 August 2016

Medico-legal Aspects of Delay in Diagnosis of Breast Cancer

As a capricious and heterogeneous disease breast cancer may be difficult to diagnose and despite being appropriately treated may relapse unexpectedly. Governmental pressure to reduce waiting for women with breast cancer may lead some patients to suspect that very short delays may impact adversely on their prognosis. In this supercharged atmosphere of anxiety, communicational skills of breast surgeons may be constantly tested so that minor solecisms may translate into major patient dissatisfaction. With this background it is unsurprising that more patients are turning to litigation in an attempt to obtain satisfaction for what they perceive as medical negligence.
Requirements
In order for a case alleging medical negligence to be successful the claimant has to successfully negotiate at least 3 hurdles. Firstly, did the doctor  have a duty of care Thus, was the defendant the claimant’s general practitioner or a member of a hospital team to which a GP referral had been made? Incorrect advice given by a doctor to a friend or acquaintance does not make that individual liable since they do not have a duty of care.


Secondly were the history-taking/ clinical examination/ advice/ procedure negligent? Negligence is defined as an action which no responsible doctor would have taken. Under the normal circumstances where there are various courses of action, provided that there is a sensible body of medial opinion for a particular approach that is not negligent even though a medical expert might not agree with the defendant’s allegedly negligent advice. An example of this is sentinel node biopsy where one body of opinion advocates a combination of tadio-isotope and dye whereas others use one or the other.


If the medical expert deems that negligence has occurred, such as failing to obtain a tissue diagnosis on a solid breast mass the next hurdle is determination of causation. For causation to be established it must be shown that as a result of the negligence the claimant has suffered an injury, that is, a significant worsening of prognosis, and/or a need for more extensive surgery or radiotherapy and or a requirement for more toxic systemic therapy and/or psychological damage. At present, in claims for delay in diagnosis of breast cancer it is necessary to prove that the claimants 10-year survival has changed from being >51% to <49%. Hence a reduction from 95% to 60% or from 45% to 25% will not meet the criteria for causation. Proportional damages are not granted at present.